The American Journal of Managed Care > September 2008

The American Journal of Managed Care - September 2008

September 15, 2008 – Kathleen M. Fox, MHS, PhD; John M. Brooks, PhD; and Jennifer Kim, PharmD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
September 15, 2008 – Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP
Diabetes mellitus (DM) prediction equations developed by the Framingham Offspring Study were validated, but the point score underestimated DM risk in an HMO population.
September 15, 2008 – Eric A. Finkelstein, PhD, MHA; and Derek S. Brown, PhD
This editorial discusses the cost implication of bariatric surgery and whether or not return on investment analysis should be used to make coverage decisions.
September 14, 2008 – Kathleen A. Fairman, MA. Author reply by Michael E. Chernew, PhD, and Joseph P. Newhouse, PhD
September 14, 2008 – Christopher N. Mills, MD, MPH. Author reply by William E. Lafferty, MD, and M. Robyn Andersen, PhD, MPH
September 15, 2008 – Joel Lexchin, MD; and Barbara Mintzes, PhD
Pharmacoeconomic analyses appear to account for differences in recommendations made regarding public payment when national bodies consider the same drugs for the same indication.
September 15, 2008 – Anna N. A. Tosteson, ScD; Russel T. Burge, PhD; Deborah A. Marshall, PhD; and Robert Lindsay, MD
Osteoporosis treatment for high-risk women is cost-effective, with bisphosphonates providing the most benefit at the lowest cost.
September 15, 2008 – Kathleen M. Fox, MHS, PhD; John M. Brooks, PhD; and Jennifer Kim, PharmD
The incremental cost of disease progression among patients with metastatic stage IIIB or IV non-small cell lung cancer versus those without progression was $12,327 for 3 postprogression months.
September 15, 2008 – Mark P. Connolly, MHE; Michael S. Pollard, PhD; Stijn Hoorens, MSc; Brian R. Kaplan, MD; Selwyn P. Oskowitz, MD; and Sherman J. Silber, MD
We estimate the future net tax contributions from an IVF-conceived child to highlight that removing barriers to fertility treatments can have long-term economic benefits.
September 15, 2008 – Gregory A. Nichols, PhD; and Jonathan B. Brown, PhD, MPP
Diabetes mellitus (DM) prediction equations developed by the Framingham Offspring Study were validated, but the point score underestimated DM risk in an HMO population.
September 15, 2008 – Eric A. Finkelstein, PhD, MHA; and Derek S. Brown, PhD
This editorial discusses the cost implication of bariatric surgery and whether or not return on investment analysis should be used to make coverage decisions.
September 14, 2008 – Pierre-Yves Cremieux, PhD; Henry Buchwald, MD, PhD; Scott A. Shikora, MD; Arindam Ghosh, PhD; Haixia Elaine Yang, PhD; and Marric Buessing, BA

This study analyzes the return on investment for bariatric surgery in the United States.

September 14, 2008 – Pierre-Yves Cremieux, PhD; Henry Buchwald, MD, PhD; Scott A. Shikora, MD; Arindam Ghosh, PhD; Haixia Elaine Yang, PhD; and Marric Buessing, BA

This study analyzes the return on investment for bariatric surgery in the United States.

September 15, 2008 – Mark P. Connolly, MHE; Michael S. Pollard, PhD; Stijn Hoorens, MSc; Brian R. Kaplan, MD; Selwyn P. Oskowitz, MD; and Sherman J. Silber, MD
We estimate the future net tax contributions from an IVF-conceived child to highlight that removing barriers to fertility treatments can have long-term economic benefits.
September 15, 2008 – Joel Lexchin, MD; and Barbara Mintzes, PhD
Pharmacoeconomic analyses appear to account for differences in recommendations made regarding public payment when national bodies consider the same drugs for the same indication.
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.